{"id":"alzt-op1a","safety":{"commonSideEffects":[{"rate":null,"effect":"Amyloid-related imaging abnormalities (ARIA)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ALZT-OP1a targets multiple pathways implicated in Alzheimer's disease pathogenesis, including tau protein aggregation and neuroinflammatory processes. By addressing these mechanisms, the drug aims to slow the progression of cognitive decline in early symptomatic Alzheimer's disease patients. The compound represents a multi-target approach to disease modification rather than targeting a single molecular entity.","oneSentence":"ALZT-OP1a is a small molecule that modulates tau pathology and neuroinflammation to slow cognitive decline in Alzheimer's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:07.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cromoglicic_acid","title":"Cromoglicic acid","extract":"Cromoglicic acid (INN)—also referred to as cromolyn (USAN), cromoglycate, or cromoglicate—is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells."},"indications":{"approved":[{"name":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)"}]},"trialDetails":[{"nctId":"NCT04570644","phase":"PHASE1","title":"Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2020-08-28","conditions":"Healthy Volunteers, Alzheimer Disease","enrollment":56},{"nctId":"NCT03202147","phase":"PHASE2","title":"Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)","status":"WITHDRAWN","sponsor":"AZTherapies, Inc.","startDate":"2023-12","conditions":"Ischemic Stroke, Post-stroke Cognitive Impairment","enrollment":""},{"nctId":"NCT02547818","phase":"PHASE3","title":"Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2015-09-15","conditions":"Alzheimer's Disease","enrollment":620},{"nctId":"NCT04428775","phase":"PHASE2","title":"A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease","status":"TERMINATED","sponsor":"AZTherapies, Inc.","startDate":"2020-09-08","conditions":"Amyotrophic Lateral Sclerosis","enrollment":12},{"nctId":"NCT02482324","phase":"PHASE1","title":"Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2015-06","conditions":"Healthy Volunteers","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cromolyn, Intal","Cromolyn"],"phase":"phase_3","status":"active","brandName":"ALZT-OP1a","genericName":"ALZT-OP1a","companyName":"AZTherapies, Inc.","companyId":"aztherapies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALZT-OP1a is a small molecule that modulates tau pathology and neuroinflammation to slow cognitive decline in Alzheimer's disease. Used for Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}